ADINAZOLAM-SR IN PANIC DISORDER WITH AGORAPHOBIA - RELATIONSHIP OF DAILY DOSE TO EFFICACY

Background: We report the results from a multicenter, double-blind, ra ndomized, fixed-dose study designed to evaluate the relationship betwe en daily dose and efficacy of adinazolam-SR in patients with panic dis order with agoraphobia. Method: Patients (N = 315) were randomized to one of four treatment groups (placebo, N = 83; 30-mg group, N = 79; 60 -mg group, N = 81; and 90-mg group, N = 72) and then treated twice dai ly for 4 weeks. All treatment groups were comparable demographically. Primary efficacy measures included total number of panic attacks, glob al improvement score using the Clinical Global Impressions (CGI) scale , phobic anxiety dimension of the Symptom Checklist-90 phobic cluster, overall phobia state using the Phobia Scale, and severity of illness on the CGI. Results: The 60- and 90-mg/day adinazolam-SR treatment gro ups showed superior results when compared with the placebo group at We ek 4 while the 30-mg group did not. Treatment with adinazolam-SR was w ell tolerated, with sedation the only treatment-emergent symptom that occurred more frequently in patients treated with adinazolam-SR than p lacebo. Conclusion: These results suggest that adinazolam-SR at doses of 60-mg/day or greater administered twice daily is a safe and effecti ve treatment in selected patients with panic disorder with agoraphobia .